All-cause mortality and use of antithrombotics within 90 days of discharge in acutely ill medical patients
Charles E. Mahan(Presbyterian Healthcare Services), Alex C. Spyropoulos(Lenox Hill Hospital), An-Chen Fu(Wilmington University), Maxine D. Fisher(Wilmington University), Larry E. Fields(Janssen (United States)), Roger M. Mills(Janssen (Belgium)), Judith J. Stephenson(Wilmington University)
Cited by 2
Related Papers
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism
|European Heart Journal|2014|3.1k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH
|Journal of Thrombosis and Haemostasis|2015|1.4k
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation
|New England Journal of Medicine|2015|1.2k
Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients
|New England Journal of Medicine|2013|603